Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
MRTX

Mirati Therapeutics Inc

MRTX

56.49USD-0.20 (-0.35%)Market Closed
Watchlist

Market Summary

USD56.49-0.20
Market Closed
-0.35%

MRTX Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

MRTX Stock Price

View Fullscreen

MRTX RSI Chart

MRTX Valuation

Market Cap

4.0B

Price/Earnings (Trailing)

-5.46

Price/Sales (Trailing)

103.7

EV/EBITDA

-2.35

Price/Free Cashflow

-6.65

MRTX Price/Sales (Trailing)

MRTX Profitability

EBT Margin

-3918.49%

Return on Equity

-85.44%

Return on Assets

-71.3%

Free Cashflow Yield

-15.05%

MRTX Fundamentals

MRTX Revenue

Revenue (TTM)

38.2M

Revenue Y/Y

201.97%

Revenue Q/Q

19.8%

MRTX Earnings

Earnings (TTM)

-725.9M

Earnings Y/Y

6.72%

Earnings Q/Q

8.48%

Price Action

Last 7 days

-1.0%

Last 30 days

0.9%

Last 90 days

58.4%

Trailing 12 Months

28.8%

How does MRTX drawdown profile look like?

MRTX Financial Health

Current Ratio

7.54

MRTX Investor Care

Shares Dilution (1Y)

21.79%

Diluted EPS (TTM)

-12.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202318.9M27.2M38.2M0
202257.2M42.3M27.4M12.4M
202128.1M42.7M57.4M72.1M
20205.9M8.4M10.9M13.4M
20194.7M5.3M6.3M3.3M
201800012.9M
20170000
20160000
20150000
20140000
20130000
20120000
20110003.1M

Latest Insider Trading transactions for MRTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 08, 2023
ondrey aaron
acquired
299,972
35.66
8,412
interim cfo
Sep 08, 2023
christensen jamie
sold
-85,084
35.63
-2,388
evp & chief scientific officer
Aug 11, 2023
boxer capital, llc
bought
33,400,000
27.8
1,201,440
-
Aug 11, 2023
boxer capital, llc
bought
1,599,420
27.8
57,533
-
Aug 11, 2023
hasnain faheem
bought
299,990
27.8
10,791
-
Aug 09, 2023
stelzer laurie
acquired
824,989
37.00
22,297
chief financial officer
Aug 09, 2023
hickey benjamin
acquired
824,989
37.00
22,297
evp, chief commercial officer
Aug 09, 2023
christensen jamie
acquired
824,989
37.00
22,297
evp & chief scientific officer
Aug 09, 2023
moriarty john b
acquired
824,989
37.00
22,297
chief legal officer
Aug 09, 2023
sandler alan b.
acquired
824,989
37.00
22,297
chief medical officer

1–10 of 50

Which funds bought or sold MRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
added
132
4,421,260
6,867,410
-%
Nov 30, 2023
Neo Ivy Capital Management
new
-
1,077,000
1,077,000
0.47%
Nov 24, 2023
DEUTSCHE BANK AG\
added
2.99
2,056,290
10,566,000
0.01%
Nov 21, 2023
COMERICA BANK
reduced
-91.11
-54,767
56,233
-%
Nov 21, 2023
Walleye Trading LLC
new
-
30,448
30,448
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
sold off
-100
-7,056,910
-
-%
Nov 16, 2023
Creative Planning
new
-
6,534
6,534
-%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
sold off
-100
-10.00
8.00
-%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
added
63.49
1,935,000
3,927,500
-%
Nov 15, 2023
HARBOUR INVESTMENTS, INC.
sold off
-100
-3,613
-
-%

1–10 of 39

Latest Funds Activity

Are funds buying MRTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MRTX
No. of Funds

Schedule 13G FIlings of Mirati Therapeutics Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Oct 12, 2023
boxer capital, llc
4.8%
3,534,249
SC 13D/A
Oct 02, 2023
ecor1 capital, llc
8.5%
5,748,399
SC 13G
Aug 16, 2023
boxer capital, llc
4.8%
3,534,249
SC 13D/A
Feb 14, 2023
armistice capital, llc
6.06%
3,488,000
SC 13G
Feb 14, 2023
avoro capital advisors llc
9.6%
5,555,555
SC 13G/A
Feb 14, 2023
rtw investments, lp
6.3%
3,643,114
SC 13G
Feb 14, 2023
perceptive advisors llc
3.8%
2,191,425
SC 13G/A
Feb 09, 2023
vanguard group inc
8.64%
4,973,888
SC 13G/A
Feb 06, 2023
wellington management group llp
5.24%
3,016,335
SC 13G/A
Feb 15, 2022
perceptive advisors llc
5.9%
3,283,783
SC 13G/A

Recent SEC filings of Mirati Therapeutics Inc

View All Filings
Date Filed Form Type Document
Dec 06, 2023
DEFA14A
DEFA14A
Dec 01, 2023
DEFA14A
DEFA14A
Nov 24, 2023
8-K
Current Report
Nov 15, 2023
DEFA14A
DEFA14A
Nov 13, 2023
8-K
Current Report
Nov 06, 2023
10-Q
Quarterly Report
Nov 06, 2023
8-K
Current Report
Nov 02, 2023
DEFM14A
DEFM14A
Oct 23, 2023
PREM14A
PREM14A
Oct 13, 2023
DEFA14A
DEFA14A

Peers (Alternatives to Mirati Therapeutics Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.5B
-
6.13% 411799.31%
-3.7K
218.4K
- -102.45%
30.6B
10.7B
12.59% -56.51%
-8.83
2.87
-53.67% -129.46%
21.3B
1.7B
0.38% -28.56%
-41.84
12.38
79.37% 56.87%
17.5B
2.3B
8.71% -10.95%
119.09
7.58
15.05% 75.21%
12.3B
3.6B
1.18% -34.97%
28.84
3.4
8.35% -51.49%
MID-CAP
7.4B
272.9M
33.62% 24.68%
-12.26
27.23
141.38% 4.43%
5.7B
-
10.65% 240.88%
-9.69
48.33
54.84% -12.96%
3.4B
631.9M
-9.53% 43.40%
-23.12
5.44
23.54% 31.53%
3.3B
223.4M
14.00% -9.85%
-16.45
14.86
- -26.24%
2.6B
240.7M
-11.63% -24.14%
-12.52
10.67
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
12.92% -15.71%
24.33
4.33
81.69% -7.29%
661.3M
1.0B
-18.09% -67.84%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.35%
-0.61
15.6
-44.11% 50.48%
37.6M
-
385.71% 119.35%
-0.58
-
- -29.23%
23.7M
-
40.31% 4064.72%
-0.5
-
- -13.74%

Mirati Therapeutics Inc News

Latest updates
Yahoo Finance08 Dec 202305:21 pm14 hours ago
MarketBeat08 Dec 202304:15 pm15 hours ago
Nasdaq04 Dec 202303:55 pm4 days ago
PR Newswire30 Nov 202304:37 pm8 days ago
Insider Monkey30 Nov 202301:03 pm8 days ago
PR Newswire29 Nov 202303:45 pm9 days ago
Pharmaceutical Technology27 Nov 202308:00 am11 days ago
Nasdaq23 Nov 202308:00 am15 days ago
Nasdaq20 Nov 202308:00 am18 days ago
Nasdaq16 Nov 202308:00 am22 days ago
Stockhouse Publishing15 Nov 202308:00 am23 days ago
GlobeNewswire09 Nov 202308:00 am29 days ago
Business Wire08 Nov 202308:00 am30 days ago
Yahoo Finance06 Nov 202308:00 am32 days ago
Nasdaq06 Nov 202308:00 am32 days ago

Financials for Mirati Therapeutics Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue19.8%16,400,00013,690,0007,167,000934,0005,431,0005,362,0002,830,500299,00071,793,00048,431,33325,069,6671,708,00011,424,0007,791,3334,158,667526,000988,000577,0001,244,0003,459,000-
Operating Expenses-6.2%188,454,000200,960,000200,990,000212,657,000191,874,000182,567,000184,927,000197,374,000151,292,000164,186,000132,421,000108,043,000100,102,00084,862,00089,754,00075,173,00058,047,00048,218,00044,002,00033,131,00028,939,000
  S&GA Expenses-4.6%72,001,00075,490,00073,490,00070,821,00060,798,00054,228,00053,951,00043,535,00035,183,00029,611,00028,350,00025,338,00020,249,00019,779,00018,046,00012,232,50010,685,0009,894,0009,762,0006,373,0005,313,000
  R&D Expenses-7.6%114,766,000124,187,000126,683,000141,236,000131,076,000128,339,000130,976,000153,839,000116,109,000134,575,000104,071,00082,705,00079,853,00065,083,00071,708,00062,940,50047,362,00038,324,00034,240,00026,758,00023,626,000
EBITDA Margin----39.01-59.30----173-106-107-107-107-104-63.94-63.94-63.94-15.70-18.64---
Income Taxes----254,000254,000---3,299,000------------
Earnings Before Taxes-----202,221,000-173,307,000---199,620,000-76,755,000---101,087,000-87,336,000--------
EBT Margin----39.18-59.53----173-106-107-107-107-104-63.94-63.94-63.94-15.70-18.64---
Net Income8.5%-161,904,000-176,913,000-184,586,000-202,475,000-173,561,000-176,445,000-188,386,000-199,620,000-80,054,000-166,430,000-135,680,000-101,087,000-87,336,000-82,859,000-86,655,000-72,376,000-54,273,000-45,695,000-40,912,000-28,272,000-27,568,000
Net Income Margin----39.01-59.57----174-144-147-122-107-98.72-88.80-77.66-63.94-26.99-26.98---
Free Cashflow----190,451,000-129,610,000-139,049,000-145,153,000-161,609,000-140,634,000-49,041,000-97,397,000-111,523,000-77,927,000-78,199,000-60,544,000-59,228,000-43,234,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets23.5%1,1309151,0341,2031,3031,2801,4211,5891,2531,3561,3811,476620664713432471501309228248
  Current Assets26.5%1,0368199391,1091,2261,2031,3431,5081,1721,2781,3041,404595654705424465496306227246
    Cash Equivalents99.7%25913024223529926630541424328133088613113220547.0092.0025275.0033.00117
  Inventory133.2%20.009.004.003.00-----------------
  Net PPE-4.9%16.0017.0017.0018.0018.0017.0017.0016.0014.0012.009.008.006.003.002.002.001.000.000.000.000.00
Liabilities-1.5%18318617120617416817219216922712111569.0059.0057.0050.0036.0029.0026.0027.0023.00
  Current Liabilities-1.9%13714012515912711912414412218177.0071.0067.0058.0056.0049.0035.0028.0025.0026.0022.00
Shareholder's Equity29.8%9467298639971,1291,1121,2491,3971,0841,1291,2591,361551605656382434472284202225
  Retained Earnings-5.8%-2,976-2,814-2,637-2,452-2,250-2,076-1,900-1,712-1,512-1,432-1,265-1,130-1,029-941-858-772-699-645-599-559-530
  Additional Paid-In Capital10.7%3,9243,5453,5023,4533,3863,1853,1453,1002,5872,5522,5162,4811,5701,5351,5051,1451,1241,108874751746
Shares Outstanding20.2%70.0058.0058.0058.0058.0056.0055.0055.0052.0051.0051.0050.0045.0044.0043.0040.0037.0036.0035.0031.0030.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-9.4%-143,713-131,400-190,182-128,800-137,809-143,492-160,469-137,985-47,032-93,367-110,416-76,421-76,763-59,343-59,004-41,902-32,874-38,468-34,482-20,795-20,172
  Share Based Compensation13.1%44,55339,39946,96161,60742,99238,68442,90533,87826,93327,96924,72221,74321,75020,78721,56716,71115,10612,58911,1314,2624,058
Cashflow From Investing-500.4%-62,19415,532195,15159,29713,945103,00649,555-170,83870436,761-455,528-59,34064,157-22,447-122,227-6,939-128,066-5,927-35,208-63,68328,762
Cashflow From Financing8609.3%334,7003,8431,7275,920157,1051,3922,527479,2828,2327,8239,885889,88912,3519,273339,2013,4731,072221,882111,6014622,157

MRTX Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenue$ 16,400$ 5,431$ 37,257$ 11,502
Revenue    
Total revenue16,4005,43137,25711,502
Operating expenses    
Cost of product revenue1,42803,0110
Cost of product revenue - intangible asset amortization25907760
Research and development114,766131,076365,636390,391
Selling, general and administrative72,00160,798220,981168,977
Total operating expenses188,454191,874590,404559,368
Loss from operations(172,054)(186,443)(553,147)(547,866)
Other income, net10,15013,13629,7449,728
Loss before income taxes(161,904)(173,307)(523,403)(538,138)
Income tax expense02540254
Net loss(161,904)(173,561)(523,403)(538,392)
Unrealized gain (loss) on available-for-sale investments106(1)2,175(5,712)
Foreign currency translation adjustment59(9,485)(6)(9,485)
Comprehensive loss$ (161,739)$ (183,047)$ (521,234)$ (553,589)
Basic net loss per share (USD per share)$ (2.49)$ (3.09)$ (8.66)$ (9.66)
Diluted net loss per share (USD per share)$ (2.49)$ (3.09)$ (8.66)$ (9.66)
Weighted average common shares outstanding, basic (shares)64,993,07956,219,41660,419,75555,747,205
Weighted average common shares outstanding, diluted (shares)64,993,07956,219,41660,419,75555,747,205
Product Revenue    
Total revenue$ 16,400$ 0$ 36,056$ 0
Revenue    
Total revenue16,400036,0560
License and Collaboration Revenue    
Total revenue05,4311,20111,502
Revenue    
Total revenue$ 0$ 5,431$ 1,201$ 11,502

MRTX Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 258,718$ 235,260
Short-term investments717,716848,577
Accounts receivable, net14,651865
Inventory20,1563,020
Other current assets24,83921,239
Total current assets1,036,0801,108,961
Property and equipment, net16,04617,540
Intangible asset, net14,13814,914
Long-term investment3,5593,465
Right-of-use asset35,06636,122
Other long-term assets24,81921,645
Total assets1,129,7081,202,647
Current liabilities  
Accounts payable37,96138,861
Accrued liabilities99,418120,587
Total current liabilities137,379159,448
Lease liability42,20343,661
Other liabilities3,6613,022
Total liabilities183,243206,131
Commitments and contingencies (see Note 11)
Shareholders' equity  
Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both September 30, 2023 and December 31, 202200
Common stock, $0.001 par value; 100,000,000 authorized; 70,111,309 and 57,854,559 issued and outstanding at September 30, 2023 and December 31, 2022, respectively7058
Additional paid-in capital3,924,2373,453,066
Accumulated other comprehensive loss(1,550)(3,719)
Accumulated deficit(2,976,292)(2,452,889)
Total shareholders' equity946,465996,516
Total liabilities and shareholders' equity$ 1,129,708$ 1,202,647
MRTX
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
 CEO
 WEBSITEwww.mirati.com
 EMPLOYEES587

Mirati Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Mirati Therapeutics Inc? What does MRTX stand for in stocks?

MRTX is the stock ticker symbol of Mirati Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mirati Therapeutics Inc (MRTX)?

As of Fri Dec 08 2023, market cap of Mirati Therapeutics Inc is 3.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRTX stock?

You can check MRTX's fair value in chart. The fair value of Mirati Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mirati Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mirati Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MRTX is over valued or under valued. Whether Mirati Therapeutics Inc is cheap or expensive depends on the assumptions which impact Mirati Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRTX.

What is Mirati Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, MRTX's PE ratio (Price to Earnings) is -5.46 and Price to Sales (PS) ratio is 103.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Mirati Therapeutics Inc's stock?

In the past 10 years, Mirati Therapeutics Inc has provided 0.128 (multiply by 100 for percentage) rate of return.